Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.
Ocean AJ, Christos P, Sparano JA, Matulich D, Kaubish A, Siegel A, Sung M, Ward MM, Hamel N, Espinoza-Delgado I, Yen Y, Lane ME. Ocean AJ, et al. Among authors: hamel n. Cancer Chemother Pharmacol. 2011 Aug;68(2):379-88. doi: 10.1007/s00280-010-1481-z. Epub 2010 Oct 28. Cancer Chemother Pharmacol. 2011. PMID: 20981545 Free PMC article. Clinical Trial.
Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase.
Hajjar KA, Hamel NM. Hajjar KA, et al. Among authors: hamel nm. J Biol Chem. 1990 Feb 15;265(5):2908-16. J Biol Chem. 1990. PMID: 2154465 Free article.
Previous work from this laboratory (Hajjar, K.A., Hamel, N. M., Harpel, P. C., and Nachman, R. L. (1987) J. Clin. Invest. 80, 1712-1719) has demonstrated dose-dependent, saturable, and high affinity binding of t-PA to two sites associated with cultural endothelial c …
Previous work from this laboratory (Hajjar, K.A., Hamel, N. M., Harpel, P. C., and Nachman, R. L. (1987) J. Clin. Invest. 80, …
Universal Genetic Testing for Newly Diagnosed Invasive Breast Cancer.
Rezoug Z, Totten SP, Szlachtycz D, Atayan A, Mohler K, Albert S, Feng L, Lemieux Anglin B, Shen Z, Jimenez D, Hamel N, Meti N, Esfahani K, Boileau JF, Prakash I, Basik M, Meterissian S, Tremblay F, Fleiszer D, Anderson D, Chong G, Wong SM, Foulkes WD. Rezoug Z, et al. Among authors: hamel n. JAMA Netw Open. 2024 Sep 3;7(9):e2431427. doi: 10.1001/jamanetworkopen.2024.31427. JAMA Netw Open. 2024. PMID: 39226054 Free PMC article.
Long-term tumour dormancy in a BRCA1 heterozygote.
Amuzu S, Fu L, Demko N, Rivera B, Domecq C, de Kock L, Hamel N, Gilbert L, Polak P, Ragoussis J, Foulkes WD. Amuzu S, et al. Among authors: hamel n. J Med Genet. 2023 Jan;60(1):33-35. doi: 10.1136/jmedgenet-2021-108269. Epub 2022 Jan 17. J Med Genet. 2023. PMID: 35039446 No abstract available.
125 results